Obesity Science Board Meeting Could Include Comparisons Of Marketed Drugs
This article was originally published in The Pink Sheet Daily
Discussion topics for the April 22 FDA meeting include cardiovascular endpoints and a revision of a 1996 draft guidance for weight control agents.
You may also be interested in...
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.
Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.
FDA extends the combination vaccine’s action date for the second time, this time requesting lab validation information relating to the pertussis component, but not directly related to Pentacel.